Formulated for breast cancer to target estrogen levels and support tumor growth inhibition.
Mechanism of Action
Letrozole competitively inhibits the aromatase enzyme, which converts androgens to estrogens. This reduction in estrogen suppresses growth in estrogen-receptor-positive breast cancer cells.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
2–3 days
Contraindications
Hypersensitivity to letrozole, Premenopausal status, Pregnancy
Severe Adverse Events
Osteoporosis, Fractures, Thromboembolic events — requires immediate medical attention
Information related to Femara is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
